Yükleniyor... / Loading...
This study evaluates whether tumor-derived somatic mutations (including HRD and BRCA mutations) can be detected in the blood of patients with ovarian cancer. It included patients aged 18 and older with untreated advanced or recurrent high-grade ovarian cancer. It was conducted as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥ 18 years * Patient with stage III to IV non-treated high grade ovarian cancer or recurrent high grade ovarian cancer * Adequate haemoglobin rate ≥ 9 g/dL * Patient who can benefit from an additional blood sample of 20ml. The total volume of each sample meets with the indications of the Order in force establishing the list of researches mentioned in 2 ° of Article L. 1121-1 of the Public Health Code. * Availability of tumor samples from biopsy or surgery * Patient affiliated to a social security scheme * Ability to provide written informed consent Exclusion Criteria: * Any concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study * Contraindication to a blood sample of 20 mL * Pregnant or breast-feeding women * Ongoing treatment for the newly diagnosed cancer or the recurrence * Patient pre-treated with poly-ADP-ribose-polymérase-1 (PARP) Inhibitors * Patient under guardianship or curatorship or deprived of liberty.